P. van der Valk (Enschede, Netherlands), V. Poletti (Forli, Italy)
Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB)
S. Sethi, F. Kruesmann, D. Haverstock, R. Peroncel, S. Choudhri (Buffalo, NY, West Haven, CT, United States Of America; Leverkusen, Germany; Toronto, ON, Canada)
|   |
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Y. Watanuki, N. Miyazawa, M. Kudo, S. Inoue, H. Goto, T. Kaneko, H. Takahashi, Y. Ishigatsubo (Yokohama, Japan)
| |
Association of NRAMP1 gene polymorphisms with COPD clinical signs
E. Bukreeva, G. Seitova (Tomsk, Russian Federation)
| |
HI-164, an oral vaccine to non-typable haemophilus influenzae, reduces antibiotic use, respiratory exacerbations and hospitalisations in patients with COPD
M. Phillips, M. Tandon, G. Waterer, M. Dunkley, R. Clancy (Perth, Newcastle, NSW, Australia)
| |
Procalcitonin-guided assessment of bacterial etiological role in patients admitted for severe COPD exacerbations: a double-blind study
R. Dal Negro, M. Caputo, S. Bertacco, A. Conti, C. Micheletto (Bussolengo, VR, Italy)
| |
Increased intima-media thickness in stable COPD – is systemic inflammation the cause?
P. Eickhoff, D. Kiss, M. Schreder, R. Kohansal, A. Valipour, K. Geyer, O. C. Burghuber (Vienna, Austria)
| |
Factors associated with sputum purulence in stable moderate to severe COPD patients
C. Esquinas, M. Miravitlles, E. Monso, S. Vila, A. Marin, R. Hervas, M. Garcia, C. de la Roza, A. Torres, J. Morera (Barcelona, Badalona, Spain)
| |
Differences between smokers and ex-smokers in severity and mechanisms of infectious exacerbations
S. Bourne, G. Seumois, M. Ben, D. Ratko (Southampton, United Kingdom)
| |
Quinolones consume and streptococcus pneumoniae antibiotic resistance
J. Tarrega, C. Marti, M. Sagales, M. Torrella, E. Barbeta (Granollers, Spain)
| |
Significant correlations between the numbers of chlamydia psittaci positive cells and all cells further indicate a role of this infectious agent in the pathogenesis of human pulmonary emphysema
O. Anhenn, T. Bexten, G. Stamatis, D. Theegarten (Essen, Germany)
| |
Clinical differences between patients admitted to hospital with an acute or non-acute exacerbation of COPD
J. Ottevanger, D. Snijders, W. Boersma (Alkmaar, Netherlands)
| |
Frequent outpatient exacerbations of non cystic fibrosis bronchiectasis leads to impaired health related quality of life
M. Murray, A. Hill (Scotland, United Kingdom)
| |
A nosocomial outbreak of corynebacterium striatum infection in patients with COPD
F. Renom, M. Garau, M. Rubi, F. Ramis, A. Galmes, J. B. Soriano (Bunyola, Palma de Mallorca, Spain)
| |
C-reactive protein usefulness in diagnosis and follow-up of COPD infectious exacerbations
X. Pomares, C. Monton, M. Gallego, D. Mariscal, E. Castaner, J. Valles, A. Marin (Sabadell, Spain)
| |
Platelet characteristics of patients with chronic obstructive pulmonary disease (COPD) accompanied with lung hypertension
G. Sadikova, A. Anis, S. Khamida (Tashkent, Uzbekistan)
| |
Antibiotic treatment in pneumonia and chronic obstructive pulmonary disease – adherence to guidelines in an English teaching hospital
A. Ghattas, R. Labib, R. Heinink, A. Mansur (Birmingham, United Kingdom)
| |
Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease
A. Bircan, M. Gokirmak, O. Kilic, O. Ozturk, A. Akkaya (Isparta, Turkey)
| |
Which patients with COPD can potentially benefit from prophylactic use of antibiotics?
A. T. Lo Tam Loi, G. I. Andriesse, R. S. Djamin (Breda, Netherlands)
| |
A retrospective study of antibiotic prescribing for patients admitted to hospital with exacerbation of COPD
S. Murphy, G. Morgan-Eshun, H. Moore, F. Bates, V. Dudzevicius, G. Antunes, N. Krishnaraj (Middlesbrough, United Kingdom; Kumasi, Ghana)
| |
Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp) in pts with acute exacerbation of chronic bronchitis (AECB)
J. Gaillat, J. Garau, S. Sethi, A. Anzueto, D. Guillemot, P. Weber (Annecy, Paris, Vaires-sur-Marne, France; Terrassa, Spain; Buffalo, NY, San Antonio, TX, United States Of America)
| |